Eflornithine

Generic Name: Eflornithine

Brand Names: Vaniqa

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂F_₂N_₂O_₂

CAS Number: 70052-12-9

Unique Ingredient Identifier: ZQN1G5V6SR

Background: Eflornithine is a prescription drug indicated in the treatment of facial hirsutism (excessive hair growth). Eflornithine hydrochloride cream for topical application is intended for use in women suffering from facial hirsutism and is sold by Allergan, Inc. under the brand name Vaniqa. Eflornithine for injection against sleeping sickness was manufactured by Sanofi Aventis and sold under the brand name Ornidyl in the USA. It is now discontinued. Eflornithine is on the World Health Organization's List of Essential Medicines.

Indication: Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth).

Associated Conditions: Meningoencephalitic stage Trypanosoma brucei gambiense infection

Associated Therapies: Hair removal therapy

Clinical Trials

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

Phase 3

Completed

Conditions: Precancerous Condition

Interventions: Other: placebo
Drug: eflornithine
Other: laboratory biomarker analysis
Drug: sulindac

First Posted Date: 2005-07-11

Last Posted Date: 2015-01-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 375

Registration Number: NCT00118365

Locations: 🇺🇸
University of California Medical Center At Irvine-Orange Campus, Orange, California, United States

Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer

Phase 3

Completed

Conditions: Non-melanomatous Skin Cancer

First Posted Date: 2004-07-26

Last Posted Date: 2019-12-13

Lead Sponsor: University of Wisconsin, Madison

Registration Number: NCT00005884

Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: eflornithine
Drug: oral bicalutamide placebo
Drug: oral eflornithine placebo

First Posted Date: 2004-07-12

Last Posted Date: 2013-11-19

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 34

Registration Number: NCT00086736

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Phase 2

Completed

Conditions: Cervical Cancer
Precancerous Condition

Interventions: Other: Placebo
Drug: Eflornithine

First Posted Date: 2004-05-26

Last Posted Date: 2018-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 150

Registration Number: NCT00006079

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus

Phase 2

Completed

Conditions: Esophageal Cancer

First Posted Date: 2004-04-23

Last Posted Date: 2012-12-19

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 152

Registration Number: NCT00003076

Locations: 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 2 locations

Eflornithine in Treating Patients With Bladder Cancer

Phase 3

Completed

Conditions: Bladder Cancer

First Posted Date: 2004-02-20

Last Posted Date: 2013-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 450

Registration Number: NCT00003814

Locations: 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸
Piedmont Urology PC, Atlanta, Georgia, United States

and more 58 locations